Group 1: New Stock Listings Performance - Four new stocks, including Impression Da Hong Pao, Huazhang Biotech, Mingji Hospital, and Nanhua Futures, debuted but all experienced a decline on their first trading day [1] Group 2: Huazhang Biotech - Huazhang Biotech opened at HKD 33.8, which is 11.5% lower than the IPO price of HKD 38.2, resulting in a loss of HKD 880 per lot of 200 shares [2] - The company focuses on wound healing therapies and is an unprofitable biotech firm specializing in developing protein drugs, particularly platelet-derived growth factor (PDGF) drugs [2] - The company did not attract cornerstone investors, with Huatai International and CITIC Securities serving as joint sponsors [3] Group 3: Mingji Hospital - Mingji Hospital opened at HKD 6.5, down 30.4% from the IPO price of HKD 9.34, leading to a loss of HKD 1,420 per lot of 500 shares [4] - The company operates as a large private profit-oriented hospital group in East China, primarily managing two tertiary hospitals in Nanjing and Suzhou, with a focus on orthopedics, cardiovascular, oncology, and reproductive medicine [4] - Cornerstone investors include He Rong Technology, He Fu (China), and Suzhou Zhanxing, collectively subscribing to 49.63% of the total offering [5] Group 4: Impression Da Hong Pao - Impression Da Hong Pao opened at HKD 3.26, which is 9.4% lower than the IPO price of HKD 3.6, resulting in a loss of HKD 340 per lot of 1,000 shares [6] - The company operates based on Wuyi Mountain tea culture, providing tourism performances and related services, with its core revenue source being the live performance "Impression Da Hong Pao," accounting for over 85% of its income [6] - The company was oversubscribed by over 3,400 times, with joint sponsors being Xingsheng International and Kaisen [6] Group 5: Nanhua Futures - Nanhua Futures opened at HKD 9.13, down 23.9% from the IPO price of HKD 12, leading to a loss of HKD 1,435 per lot of 500 shares [7] - The company is a futures brokerage listed on the A-share main board, primarily engaged in futures brokerage, investment consulting, asset management, and securities investment fund distribution, focusing on derivative business [7] - CITIC Securities is the sole sponsor for the company [7]

Core Viewpoint - The recent IPO of Ming Kee Hospital (02581.HK) and three other stocks on the Hong Kong Stock Exchange faced significant declines on their debut, with Ming Kee Hospital experiencing the largest drop of over 38.5% from its issue price of 9.34 HKD to approximately 5.74 HKD [2][3]. Group 1: IPO Performance - Four new stocks, including Ming Kee Hospital, were listed on December 22, with all experiencing a drop on their first trading day [2]. - Ming Kee Hospital had a subscription rate of 6.28 times during the public offering phase, with 670,000 shares allocated, representing about 10% of the total shares [2]. - The international placement phase saw a subscription rate of 1.28 times, with 60.3 million shares allocated, accounting for 90% of the total shares [2]. Group 2: Company Overview - Ming Kee Hospital is a private profit-oriented general hospital group in mainland China, operating two hospitals with a total of 1,850 registered beds and over 1,000 experienced doctors, including 35 experts from Taiwan and overseas [3]. - The hospital group is projected to serve over 2 million outpatient visits and perform over 22,000 inpatient surgeries in 2024 [3]. - According to Frost & Sullivan, Ming Kee Hospital is the largest private profit-oriented general hospital group in East China, holding a market share of 1.0% based on total revenue for 2024 [3]. Group 3: Financial Performance - Ming Kee Hospital's revenue from 2022 to the first half of 2025 is projected to be 2.336 billion RMB, 2.688 billion RMB, 2.659 billion RMB, and 1.312 billion RMB, respectively, with corresponding profits of 90 million RMB, 167 million RMB, 109 million RMB, and 49 million RMB [3]. - There has been a noticeable decline in profit performance in recent years [3].

Group 1 - The core viewpoint of the article is that Mingji Hospital (02581) has listed its shares, but the stock price fell significantly on its first trading day, opening down 30.41% [1] - The company priced its shares at HKD 9.34 each and issued 67 million shares, raising approximately HKD 555 million in net proceeds [1] - As of the report, the stock was trading at HKD 6.5 with a transaction volume of HKD 8.6846 million [1] Group 2 - Mingji Hospital is the largest private profit-oriented comprehensive hospital group in East China, operating Nanjing Mingji Hospital and Suzhou Mingji Hospital [1] - According to Frost & Sullivan data, the company holds a 1.0% market share in East China based on total revenue for 2024, ranking seventh among private profit-oriented hospital groups nationwide with a 0.4% market share [1] - The company ranks first in bed revenue among all private profit-oriented hospital groups in mainland China for 2024 [1]

Core Viewpoint - Ming Kee Hospital is set to list on the Hong Kong Stock Exchange after multiple attempts, with its IPO expected to take place between December 12 and December 22, 2023, despite previous setbacks due to compliance and operational issues [1][2]. Company Overview - Ming Kee Hospital is a private profit-oriented general hospital group in mainland China, operating two hospitals in Nanjing and Suzhou, with a valuation of approximately $375 million after the last round of equity transactions [2]. Financial Performance - For the years 2022 to 2024, the company's revenue is projected to be RMB 2.336 billion, RMB 2.688 billion, and RMB 2.659 billion respectively, with net profit expected to rise from RMB 89.55 million in 2022 to RMB 168.03 million in 2023, before declining to RMB 108.92 million in 2024 [3][5]. - In the first half of 2023, the hospital reported revenue of RMB 1.312 billion, with a net profit of only RMB 49 million, reflecting a year-on-year decline of over 23% [3][5]. Market Position - Ming Kee Hospital ranks as the largest private profit-oriented general hospital group in East China and seventh nationwide, holding a market share of 0.4% [3]. Operational Challenges - The fluctuation in net profit is attributed to the current medical insurance payment policies, particularly the DRG payment system, which has led to a decrease in average patient spending per hospitalization [4]. Growth Strategy - To overcome growth bottlenecks, Ming Kee Hospital plans to expand its operational scale, with plans to add at least 1,800 beds across its two hospitals over the next six years [5]. IPO Structure and Market Response - The company is utilizing the new IPO allocation mechanism "Mechanism B," which allows for a predetermined allocation of shares to public offerings, with 10% allocated for public sale and 90% for international placement [7][8]. - The IPO price range is set between HKD 9.34 and HKD 11.68, aiming to raise up to HKD 780 million, but the high valuation has led to lukewarm market reception, with the stock trading below the IPO price shortly after listing [10].

智通财经APP讯，明基医院(02581)公布配发结果，公司全球发售6700万股股份，香港公开发售占10%， 国际发售占90%。每股发售价9.34港元，全球发售净筹约5.55亿港元。每手500股股份，预期股份将于 2025年12月22日上午九时正(香港时间)开始在联交所买卖。 其中，香港公开发售获6.28倍认购，国际发售获1.28倍认购。 ...

明基医院(02581)公布配发结果，公司全球发售6700万股股份，香港公开发售占10%，国际发售占90%。 每股发售价9.34港元，全球发售净筹约5.55亿港元。每手500股股份，预期股份将于2025年12月22日上午 九时正(香港时间)开始在联交所买卖。 其中，香港公开发售获6.28倍认购，国际发售获1.28倍认购。 ...

格隆汇12月19日丨明基医院(02581.HK)公告，公司全球发售67,000,000股，每股9.34港元，所得款项净 额5.55亿港元。香港公开发售股份数目占全球发售股份数目10%，获认购6.28倍；国际发售股份数目占 全球发售股份90%，获认购倍1.28倍。 假设全球发售于2025年12月22日(星期一)上午八时正(香港时间)或之前成为无条件，预期股份将于2025 年12月22日(星期一)上午九时正开始在联交所交易。股份将以每手500股股份进行交易。股份的股份代 号为2581。 ...

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 本公告不會直接或間接於或向美國（包括其領土及屬地、美國任何州及哥倫比亞特區）發佈、刊 發、派發。本公告並不亦無意構成或組成在美國境內或於任何其他司法權區購買或認購證券的 任何要約或招攬的一部分。發售股份並無亦不會根據1933年美國證券法（經不時修訂）（「美國證 券法」）或美國任何州或其他司法權區的證券法登記，且不得在美國境內提呈發售、出售、質押 或以其他方式轉讓，惟於獲豁免或毋須遵守美國證券法的登記規定及遵守任何適用州證券法的 交易除外。發售股份乃根據美國證券法S規例以及該等發售及銷售所在地各司法權區的適用法 律僅於美國境外以離岸交易方式提呈發售及出售。發售股份不會在美國公開發售。 本公告僅供參考，並不構成收購、購買或認購證券的邀請或要約。本公告並非招股章程。潛在 投資者在決定是否投資於所提呈發售的發售股份前，應細閱明基醫院集團股份有限公司（「本公 司 ...

来源：智通财经网 从财务角度来看，招股书显示，2022年至2024年，公司收入分别为23.36亿元、26.88亿元和26.59亿元; 对应年内利润则由2022年的8955万元大幅增长至2023年的1.68亿元，但在2024年下滑至1.09亿元。整体 来看，2024年，明基医院收入增长出现停滞，并出现一定盈利波动。 顶着2024年中国内地所有民营营利性综合医院集团排名第一的光环，明基医院（02581）四闯港市，最 终赶在今年年末敲开港交所大门，于12月12日至12月17日完成招股后，预期在12月22日挂牌交易。 而在今年上半年，明基医院收入为13.12亿元，净利润却仅有0.49亿元，同比下滑超过23%;经营活动产 生的现金流量净额为8012.9万元，同比下降52.05%。对于营收下滑，公司在招股书中表示，主要由于 2024年初传染病疫情较2025年同期更为严重，门诊患者就诊次数减少，导致2025上半年门诊医疗服务产 生的收入减少，并抵消了同期住院医疗服务收入的增加。 回顾明基医院的赴港之旅，其首次向港交所递交招股书的时间在去年4月，后因申请材料不完备、合规 风险和业务模式缺陷等原因，未能在六个月内通过上市聆讯， ...

明基医院(02581)将于2025年12月22日(星期一)在香港挂牌。截至收盘，利弗莫尔证券暗盘交易显示报价6.97港元，较招股价9.34港元下跌25.37%，每手500 股，不计手续费，每手亏1185港元。 18:30 TITT 17:30 16:15 18:00 17:00 स्थिय 日K 1分 5分 • 行情来源: 利弗莫尔证券 • | 明基医院 ( HK 02581 暗盘 | | ಇ ರ | | | --- | --- | --- | --- | | 6.970 | | 今开 9.340 | | | 最低 6.710 -25 27% -2 270 - 央于 0.22% - - - - - - | | 总市 21.74亿 | | | 20251219 18:30 价 6.970 -25.37% 均 7.179 分时量 0股 | | | | | 11.970 | 28.16% | 十档 | 成交明细 | | | | 7.080 | - - (- -) | | | | 7.070 | - -(- -) | | | | 7.060 | - -(- -) | | | | 7.050 | - -(- -) | ...